Samsung Biologics Acquires PolyPeptide Group for 2.7 Trillion Won in Largest Korean Pharma M&A
Samsung Biologics disclosed on the 20th that it will acquire 100% of PolyPeptide Group for 1.46 billion Swiss francs (approximately 2.7 trillion Korean won), the largest pharmaceutical merger and acquisition in Korean industry history. The acquisition expands Samsung Biologics' contract
Samsung Biologics-2.71%
GateMacroTradfiHub·07-20 00:51
